Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wou… Read more
Rafarma Pharmaceuticals Inc (RAFA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.000x
Based on the latest financial reports, Rafarma Pharmaceuticals Inc (RAFA) has a cash flow conversion efficiency ratio of 0.000x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.00K) by net assets ($10.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rafarma Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Rafarma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rafarma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rafarma Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Titon Holdings Plc
LSE:TON
|
0.094x |
|
IFCM3F
SA:IFCM3F
|
N/A |
|
CHINA TRAVEL INTL
BE:CTI
|
N/A |
|
SAFEROADS HLDGS
BE:S4Q
|
N/A |
|
Globa Terra Acquisition Corporation Warrants
NASDAQ:GTERW
|
N/A |
|
AMAR3F
SA:AMAR3F
|
N/A |
|
BRAVE
ST:BRAVE
|
2.059x |
|
Asiarim Corporation
PINK:ARMC
|
0.000x |
Annual Cash Flow Conversion Efficiency for Rafarma Pharmaceuticals Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Rafarma Pharmaceuticals Inc from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.38 Million | $44.00K | 0.004x | +100.09% |
| 2023-12-31 | $10.51 Million | $-50.67 Million | -4.822x | +0.33% |
| 2023-11-30 | $10.47 Million | $-50.67 Million | -4.838x | -2107.75% |
| 2022-12-31 | $77.89 Million | $18.77 Million | 0.241x | 0.00% |
| 2022-11-30 | $77.89 Million | $18.77 Million | 0.241x | +482.12% |
| 2021-12-31 | $69.50 Million | $2.88 Million | 0.041x | 0.00% |
| 2021-11-30 | $69.50 Million | $2.88 Million | 0.041x | +124.61% |
| 2020-12-31 | $52.09 Million | $-8.76 Million | -0.168x | 0.00% |
| 2020-11-30 | $52.09 Million | $-8.76 Million | -0.168x | -115.04% |
| 2019-12-31 | $9.13 Million | $10.21 Million | 1.118x | 0.00% |
| 2019-11-30 | $9.13 Million | $10.21 Million | 1.118x | +9037.70% |
| 2018-12-31 | $6.02 Million | $-75.39K | -0.013x | 0.00% |
| 2018-11-30 | $6.02 Million | $-75.39K | -0.013x | -170.94% |
| 2017-12-31 | $6.00 Million | $105.86K | 0.018x | 0.00% |
| 2017-11-30 | $6.00 Million | $105.86K | 0.018x | +811586.09% |
| 2014-12-31 | $460.05 Million | $-1.00K | 0.000x | 0.00% |
| 2014-11-30 | $460.05 Million | $-1.00K | 0.000x | -102.87% |
| 2011-11-30 | $329.75 Million | $25.00K | 0.000x | -99.35% |
| 2010-11-30 | $2.13 Million | $25.00K | 0.012x | -- |